S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave

bioAffinity Technologies (BIAF) Competitors

$2.78
-0.01 (-0.36%)
(As of 04/19/2024 ET)

BIAF vs. AIKI, TARA, LIAN, JAN, ECOR, RVP, NTRB, ACHL, INKT, and POCI

Should you be buying bioAffinity Technologies stock or one of its competitors? The main competitors of bioAffinity Technologies include AIkido Pharma (AIKI), Protara Therapeutics (TARA), LianBio (LIAN), JanOne (JAN), electroCore (ECOR), Retractable Technologies (RVP), Nutriband (NTRB), Achilles Therapeutics (ACHL), MiNK Therapeutics (INKT), and Precision Optics (POCI). These companies are all part of the "medical" sector.

bioAffinity Technologies vs.

bioAffinity Technologies (NASDAQ:BIAF) and AIkido Pharma (NASDAQ:AIKI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bioAffinity Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
AIkido Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

AIkido Pharma has lower revenue, but higher earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$2.53M12.65-$7.94M-$0.90-3.09
AIkido Pharma$10K1,480.95-$7.17M-$3.88-0.70

AIkido Pharma has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -313.34%. AIkido Pharma's return on equity of -18.21% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity Technologies-313.34% -107.20% -84.10%
AIkido Pharma N/A -18.21%-16.94%

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 8.6% of AIkido Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AIkido Pharma received 101 more outperform votes than bioAffinity Technologies when rated by MarketBeat users.

CompanyUnderperformOutperform
bioAffinity TechnologiesN/AN/A
AIkido PharmaOutperform Votes
101
63.92%
Underperform Votes
57
36.08%

In the previous week, bioAffinity Technologies had 4 more articles in the media than AIkido Pharma. MarketBeat recorded 5 mentions for bioAffinity Technologies and 1 mentions for AIkido Pharma. AIkido Pharma's average media sentiment score of 0.67 beat bioAffinity Technologies' score of 0.00 indicating that AIkido Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
bioAffinity Technologies
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AIkido Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

bioAffinity Technologies has a beta of 3.93, meaning that its share price is 293% more volatile than the S&P 500. Comparatively, AIkido Pharma has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Summary

AIkido Pharma beats bioAffinity Technologies on 9 of the 14 factors compared between the two stocks.

Get bioAffinity Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIAF and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIAF vs. The Competition

MetricbioAffinity TechnologiesCommercial physical research IndustryMedical SectorNASDAQ Exchange
Market Cap$32.00M$5.06B$4.84B$7.32B
Dividend YieldN/A1.46%2.93%3.99%
P/E Ratio-3.0911.72182.9215.24
Price / Sales12.65104.202,460.4181.79
Price / CashN/A29.2746.3134.42
Price / Book5.454.334.564.15
Net Income-$7.94M$126.81M$103.92M$214.00M
7 Day Performance17.80%-4.90%-4.51%-3.52%
1 Month Performance43.30%-11.48%-6.70%-5.50%
1 Year Performance52.75%1.19%7.73%3.52%

bioAffinity Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AIKI
AIkido Pharma
0 of 5 stars
$2.93
+2.8%
N/A-23.9%$16.07M$10,000.00-0.764
TARA
Protara Therapeutics
1.3337 of 5 stars
$2.85
+0.4%
$23.00
+707.0%
-13.7%$32.58MN/A-0.8026
LIAN
LianBio
0 of 5 stars
$0.30
+3.4%
$5.33
+1,676.6%
-86.0%$32.44MN/A-0.37163Gap Up
JAN
JanOne
0 of 5 stars
$3.82
+24.0%
N/A+274.5%$32.81M$39.61M0.00199Positive News
High Trading Volume
ECOR
electroCore
2.0274 of 5 stars
$5.51
-2.8%
$10.00
+81.5%
-17.2%$33.06M$16.03M-1.5568News Coverage
Gap Down
RVP
Retractable Technologies
0 of 5 stars
$1.07
+0.9%
N/A-42.7%$32.03M$43.60M-4.46190Analyst Report
NTRB
Nutriband
0 of 5 stars
$4.09
+4.6%
N/A+9.6%$32.03M$2.08M-6.103Upcoming Earnings
Gap Up
ACHL
Achilles Therapeutics
1.91 of 5 stars
$0.80
-2.4%
$4.00
+398.6%
-12.9%$31.99MN/A-0.46234
INKT
MiNK Therapeutics
3.1252 of 5 stars
$0.92
+1.1%
$9.00
+878.3%
-57.3%$31.92MN/A-1.3931Positive News
POCI
Precision Optics
0 of 5 stars
$5.49
+0.5%
N/A-16.3%$33.32M$21.05M-18.3084News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:BIAF) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners